Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.58 |
| ▸ | THRA | P10827 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.53 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.53 |
| ▸ | KDM6B | O15054 | 2/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027666 | 0.86 | EGLN1 (0.68) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL523085 | 0.84 | EGLN1 (0.57) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4407725 | 0.83 | EGLN1 (0.54) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL522017 | 0.82 | EGLN1 (0.72) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4413591 | 0.81 | EGLN1 (0.52) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4408921 | 0.81 | EGLN1 (0.49) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4409985 | 0.81 | EGLN1 (0.47) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4407707 | 0.81 | EGLN1 (0.54) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4412050 | 0.80 | EGLN1 (0.52) | EGLN1THRATHRBFTOBBOX1 | |
| SCHEMBL4410710 | 0.80 | THRA (0.71) | EGLN1THRATHRBFTOBBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009002533-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007047194-A2 | METHODS FOR TREATING MITF-RELATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | disclosed |